Burden of illness in adults with atopic dermatitis: Analysis of National Health and Wellness Survey data from France, Germany, Italy, Spain, and the United Kingdom | Synapse

⌘+K

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Sonelokimab, a novel IL-17A- and IL-17F-inhibiting nanobody for the treatment of moderate-to-severe hidradenitis suppurativa: a global, randomized, double-blind, placebo-controlled phase 2 clinical trial (MIRA)Journal of the American Academy of Dermatology · 2026
2Randomized Controlled Study of Nemolizumab in Patients With Chronic Kidney Disease and Associated Pruritus: Nikaia-1Journal of the American Academy of Dermatology · 2026
3Progressive extension of anifrolumab infusion intervals in responders with systemic lupus erythematosus: a multicenter prospective studyJournal of the American Academy of Dermatology · 2026
4The effects of tildrakizumab in the epigenetic aging deviation of psoriasis: A 52-week open-label studyJournal of the American Academy of Dermatology · 2026
5Comparative effectiveness of dupilumab and JAK inhibitors in atopic dermatitis: Dose reduction compromises efficacy of JAK inhibitors—The CORNERSTONE studyJournal of the American Academy of Dermatology · 2026

More from Journal of the American Academy of Dermatology

More from University of Pennsylvania